8-K: Mineralys Reports Strong Q2, Advances Hypertension Drug

Mineralys Therapeutics announced positive clinical trial results for lorundrostat in hypertension and CKD, alongside a robust cash position extending into 2027, as it prepares for an FDA pre-NDA meeting.

Summary

• Mineralys Therapeutics reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.
• Positive results from the pivotal Launch-HTN and Advance-HTN trials for lorundrostat in uncontrolled and resistant hypertension were presented at scientific meetings and published in JAMA and NEJM.
• The Explore-CKD Phase 2 trial successfully achieved statistical significance in reducing systolic blood pressure (9.25 mmHg reduction, 7.5 mmHg placebo-adjusted, p=0.0024) and urine albumin-to-creatinine ratio (30.51% reduction from baseline, 25.6% placebo-adjusted, p=0.0015) at week four, demonstrating a favorable safety profile.
• A pre-NDA meeting with the FDA is scheduled for the fourth quarter of 2025.
• The Explore-OSA Phase 2 trial for obstructive sleep apnea participants with hypertension is ongoing, with topline results anticipated in the first half of 2026.
• Cash, cash equivalents, and investments stood at $324.9 million as of June 30, 2025, up from $198.2 million on December 31, 2024.
• The company projects its current cash will fund operations into 2027.
• Net loss for Q2 2025 was $43.3 million, compared to $41.0 million for Q2 2024.
• Research and Development (R&D) expenses decreased to $38.3 million in Q2 2025 from $39.3 million in Q2 2024, primarily due to the conclusion of the lorundrostat pivotal program.
• General and Administrative (G&A) expenses increased to $8.5 million in Q2 2025 from $5.9 million in Q2 2024, mainly due to higher compensation and professional fees.

Sentiment

Score: 9

Explanation: The filing presents overwhelmingly positive clinical trial results for lorundrostat across multiple indications, including successful pivotal trials for hypertension and promising Phase 2 data for CKD. The company is on track for a pre-NDA meeting with the FDA, signaling clear progress towards commercialization. A strong cash position extending into 2027 provides significant financial stability. These factors substantially de-risk the company's profile and indicate strong operational execution.

Positives

• Lorundrostat's pivotal Launch-HTN and Advance-HTN trials met primary endpoints, demonstrating efficacy and a favorable benefit-risk profile for uncontrolled and resistant hypertension.
• Positive topline data from the Explore-CKD Phase 2 trial showed statistically significant reductions in systolic blood pressure (9.25 mmHg) and urine albumin-to-creatinine ratio (30.51% from baseline) with a favorable safety profile.
• A pre-NDA meeting with the FDA is scheduled for Q4 2025, indicating clear progress towards regulatory submission.
• Cash, cash equivalents, and investments increased significantly to $324.9 million, providing a cash runway into 2027.
• Net loss per share decreased to $(0.66) in Q2 2025 from $(0.83) in Q2 2024, despite a higher net loss, due to an increased share count.

Negatives

• Net loss increased to $43.3 million for Q2 2025 from $41.0 million for Q2 2024.
• General and Administrative expenses increased by $2.6 million year-over-year due to higher compensation and professional fees.
• Total other income, net, decreased to $3.5 million for Q2 2025 from $4.2 million for Q2 2024, primarily due to decreased interest earned on investments.

Risks

• Topline results are based on preliminary analysis and may change following a more comprehensive review of data.
• Future performance is entirely dependent on the success of lorundrostat.
• Potential delays in the commencement, enrollment, and completion of clinical trials and nonclinical studies.
• Later developments with the FDA may be inconsistent with prior feedback, and the proposed pivotal program may not support registration of lorundrostat.
• Clinical trial results, including Launch-HTN and Advance-HTN, may not be deemed sufficient by the FDA for NDA submission or regulatory approval.
• Dependence on third parties for manufacturing, research, and clinical/nonclinical testing.
• Unexpected adverse side effects or inadequate efficacy of lorundrostat may limit its development, regulatory approval, and/or commercialization.
• Unfavorable results from future clinical trials and nonclinical studies.
• Results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results.
• Macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs, and the potential for economic recession.
• Ability to maintain undisrupted business operations due to any pandemic or future public health concerns.
• Regulatory developments in the United States and foreign countries.
• Reliance on an exclusive license with Mitsubishi Tanabe Pharma for intellectual property rights to develop and commercialize lorundrostat.

Future Outlook

The company anticipates a pre-NDA meeting with the FDA in the fourth quarter of 2025, positioning it to move ahead with its New Drug Application strategy for lorundrostat. Topline results from the Explore-OSA Phase 2 trial are expected in the first half of 2026. The company believes its current cash, cash equivalents, and investments are sufficient to fund planned clinical trials, regulatory activities, and corporate operations into 2027.

Management Comments

• "We continue to lead the way in the development of ASIs for the treatment of hypertension and related cardiorenal conditions."
• "In the first half of 2025, we announced positive results from three clinical trials evaluating lorundrostat for the treatment of participants with uncontrolled or resistant hypertension."
• "These data further support our belief that lorundrostat has significant potential to be a leading new therapy to control hypertension and reduce cardiovascular risk."
• "The results from our clinical program have positioned us to move ahead with our NDA strategy, and we have scheduled a pre-NDA meeting with the FDA to take place in the fourth quarter of 2025."

Industry Context

The announcement highlights Mineralys Therapeutics' advancements in addressing significant unmet medical needs in hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA). Hypertension affects a large global population, with less than 50% achieving blood pressure goals with existing medications, and dysregulated aldosterone is a key factor in approximately 30% of cases. CKD is a leading cause of mortality, often linked to hypertension, with excess aldosterone contributing to both uncontrolled blood pressure and kidney injury. OSA impacts nearly one billion people globally, with a high comorbidity rate with hypertension, particularly resistant hypertension. Lorundrostat, as a highly selective aldosterone synthase inhibitor, targets a key underlying mechanism for these conditions, positioning it as a potential new therapeutic option in areas with significant patient populations and treatment gaps.

Comparison to Industry Standards

• The filing states that less than 50% of hypertension patients achieve their BP goal with currently available medications, indicating a significant unmet need that lorundrostat aims to address.
• It notes that dysregulated aldosterone levels are a key factor in approximately 30% of all hypertensive patients, highlighting a specific patient subgroup where lorundrostat's mechanism of action could be particularly effective.
• The reported 9.25 mmHg reduction in systolic BP (7.5 mmHg placebo-adjusted) in the Explore-CKD trial is a clinically meaningful reduction, especially given the challenges in managing hypertension in patients with reduced kidney function.
• The 30.51% reduction in UACR (25.6% placebo-adjusted) in the Explore-CKD trial suggests a positive impact on kidney function, which is crucial given that CKD affects over 10% of the global population and is a leading cause of mortality.
• The company's focus on aldosterone synthase inhibition aligns with emerging evidence pointing to dysregulated aldosterone as a key driver of both hypertension and CKD, suggesting a targeted approach to a complex disease pathology.

Stakeholder Impact

• Shareholders: Positive clinical trial results and progress towards NDA submission enhance the company's value proposition and future revenue potential. Extended cash runway reduces immediate dilution risk.
• Patients: Lorundrostat's demonstrated efficacy in hypertension and promising results in CKD offer a potential new therapeutic option for conditions with significant unmet needs.
• Employees: Continued positive clinical development and financial stability support ongoing operations and potential growth opportunities.
• Regulatory Authorities: The company's adherence to clinical trial protocols and progress towards NDA submission demonstrates commitment to regulatory processes.

Next Steps

• Conduct a pre-NDA meeting with the FDA in the fourth quarter of 2025.
• Report topline results from the Explore-OSA Phase 2 trial in the first half of 2026.
• Continue the Transform-HTN Open-Label Extension Trial to obtain additional safety and efficacy data for lorundrostat.

Key Dates

Recommendation

Mineralys Therapeutics has achieved significant clinical milestones with lorundrostat, including successful pivotal trials for hypertension and positive Phase 2 results for CKD, validating its potential as a leading therapy. The clear path to NDA submission, evidenced by a scheduled pre-NDA meeting, substantially de-risks the regulatory pathway. Furthermore, the company's robust cash position, extending into 2027, provides ample runway for continued development and commercialization efforts without immediate capital raise concerns. These factors, combined with the large unmet medical needs in hypertension and related comorbidities, position Mineralys for strong future growth and make it a compelling investment.

Keywords

Hypertension, Chronic Kidney Disease, Obstructive Sleep Apnea, Lorundrostat, Aldosterone Synthase Inhibitor, Clinical Trials, Phase 3, Phase 2, FDA, NDA, Biopharmaceutical, Cardiorenal, Drug Development